Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-A2 peptide vaccine immunization in disease-free melanoma
2006-000228-14Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MAGE-1.A2 peptide vaccine, MAGE-3.A2 peptide vaccine, MAGE-4.A2 peptide vaccine, MAGE-10.A2 peptide vaccine, MAGE-C2.A2 peptide vaccine and 5 more in cutaneous melanoma (CM) (4 arms), sponsored by Cliniques universitaires Saint-Luc. Primary endpoints: Cellular immunity against melanoma peptide antigens and Kinetics of CTL response. Started Feb 2006; status: completed.
02
Drugs
MAGE-1.A2 peptide vaccineMAGE-3.A2 peptide vaccineMAGE-4.A2 peptide vaccineMAGE-10.A2 peptide vaccineMAGE-C2.A2 peptide vaccine
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2006-000228-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000228-14.